China
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Innovent Biologics.
Under the terms of the strategic collaboration, Innovent is expected to lead programs from discovery through clinical proof of concept in China, leveraging its antibody technology platforms and clinical development capabilities.2 As part of the collaboration, Lilly will receive exclusive rights to develop and commercialize the resulting medicines worldwide outside of Greater China, while Innovent retains rights within the region.
Innovent is set to receive a $350 million upfront payment and will be eligible for development, regulatory, and commercial milestone payments totaling up to approximately $8.5 billion, contingent on future achievements. The company will also be eligible for tiered royalties on net sales outside Greater China.2
San Francisco, USA and Suzhou, China, January 2, 2025 - Innovent Biologics, Inc. (HKEX: 01801) ("Innovent"), a biopharmaceutical company dedicated to developing, manufacturing and commercializing innovative medicines for major disease areas such as oncology, autoimmunity, cardiovascular and metabolic, and ophthalmology, today announced that it has entered into an exclusive global collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to advance the development of IBI3009, a next-generation antibody-drug conjugate (ADC) candidate targeting Delta-like ligand 3 (DLL3), to provide a new treatment option for patients with advanced small cell lung cancer (SCLC). IBI3009 has received IND approval in Australia, China and the United States, and the first patient was dosed in a Phase I clinical study in December 2024.
This is the News section of the company profile page for Innovent Biologics on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
